ASX:MSB Mesoblast (MSB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Mesoblast Stock (ASX:MSB) 30 days 90 days 365 days Advanced Chart Remove Ads Get Mesoblast alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume10.19 million shsAverage VolumeN/AMarket Capitalization$2.32 billionP/E RatioN/ADividend Yield2.58%Price TargetN/AConsensus RatingN/A Company OverviewMesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More… Remove Ads Receive MSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address MSB Stock News HeadlinesThursday's HotCopper Trends: Mesoblast bags FDA tick, Hot Chili extends mine life | March 27, 2025March 27 at 3:14 AM | msn.comMesoblast kicks off Ryoncil sales in US but shareholders eager for revenueMarch 27 at 3:14 AM | msn.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. March 30, 2025 | Paradigm Press (Ad)Why Mesoblast shares could still be dirt cheap even after 700% gainMarch 5, 2025 | msn.comMesoblast share price rips 12% on financial and operational updatesFebruary 26, 2025 | msn.comMesoblast Limited: Mesoblast Financial Results and Corporate Update WebcastFebruary 26, 2025 | finanznachrichten.deRyoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation MeetingsFebruary 13, 2025 | finance.yahoo.comBullish Mesoblast Insiders Loaded Up On US$145.4m Of StockJanuary 24, 2025 | finance.yahoo.comSee More Headlines MSB Stock Analysis - Frequently Asked Questions How were Mesoblast's earnings last quarter? Mesoblast Limited (ASX:MSB) announced its quarterly earnings results on Thursday, February, 21st. The company reported ($0.09) EPS for the quarter. Mesoblast had a negative net margin of 1,490.27% and a negative trailing twelve-month return on equity of 17.79%. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include Mesoblast (MESO), Fortescue (FMG), MicroStrategy (MSTR), Aus Tin Mining (ANW), OceanaGold (OGC), Piedmont Lithium (PLL) and Alliance Resource Partners (ARLP). Company Calendar Last Earnings2/21/2019Today3/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryTrading Current SymbolASX:MSB CIKN/A Webwww.mesoblast.com Phone+61-3-96396036FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth9.56Net Income$-87,960,000.00 Net Margins-1,490.27% Pretax MarginN/A Return on Equity-17.79% Return on Assets-5.41% Debt Debt-to-Equity Ratio24.76 Current Ratio1.18 Quick Ratio1.82 Sales & Book Value Annual Sales$5.90 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow30.00 Book ValueA$0.43 per share Price / BookN/AMiscellaneous Outstanding Shares1,140,000,000Free FloatN/AMarket Cap$2.32 billion OptionableNot Optionable Beta2.38 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (ASX:MSB) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredMan Who Predicted 2008 Crash: “Move your money out of stocks TODAY”Could the recent tech sell-off indicate a looming market crash? Nvidia dropped 30% from its high... Pala...Behind the Markets | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.